Pharmaceutical corporation Celgene acquired $15m worth of series B2 stock in US-based small molecule drug company Acetylon Pharmaceuticals on Thursday. Celgene will not however, hold licensing or marketing rights to drugs currently under development at Acetylon.
Acetylon closed its series B round in June having raised $27m, while its series A round raised $9.25m over two separate tranches. Acetylon has not disclosed the identity of its private equity investors but they are thought to include holding company the Kraft Group.
…
